Abstract
Background and Purpose The pharmacotherapy options in patients with GDM, are insulin or oral antihyperglycemic agents. Insulin is the preferred medication for treating hyperglycemia, but in recent years, metformin has been increasingly used in the treatment of GDM.
The aim to assess the efficacy of different treatment (insulin and metformin) in women with GDM.
Methods Screening for GDM was performed in 2422 pregnant women and reveal GDM in 119 women (75-g OGTT was performed at 24-28 weeks of gestation). All patients started treated at 24 -29 weeks of gestations. The patients were divided into 2 groups (Gr.): Gr.1 - 68 patients, who treated with diet + insulin therapy Gr.2 - 51patients, who treated with diet + metformin.
Results At the 2nd trimester HbA1c (%) levels vas for Gr.1 and 2: 6.7 (0.05), 6.4 (0.6) respectively; By term HbA1c levels statistically decreased in both groups, but we did not found statistical difference between groups. Women from Gr.2 gained less weight compared to women from Gr.1 (1.89±3.88 vs 4.53±3.67 kg; P=0.003). In Gr.1 percent of pre-eclampsia was (2,9%) and in Gr.2(3,9%) (P= 0,7773, OR – 1,33), we did not find statistical difference between groups. The incidence of preterm delivery before 37 weeks of gestation in Gr1 was lower, than in Gr.2 (P=0.7311, OR –1,33) and we also did not find a statistical difference between groups. Perinatal mortality was observed in Gr.1 – 1.4% and in Gr.2 – 1,9% (P =0.8402, OR -1,33). In both groups we observed high percent Cesarean section (Gr.1 – 32.3% and Gr.2 – 29.4% (P=0.7651, OR -1,0909), but we did not find a statistical difference between the groups. In both groups, percent of macrosomia was high, despite good glycemic control maintained through pregnancies: 20.0% and 23.0%, for Gr.1 and Gr.2, respectively (P =0.9236, OR -1,0256), and again no statistical difference was found between the groups. Percent of neonatal hypoglycemia was lower in Gr.2 (1.9%), than in Gr.1 (4.41%) (P=0.9236, OR –1,0256).. Percent of respiratory distress syndrome was 2.94% and in 3.92% for Gr.1 and Gr.2, respectively (P= 0.9694, OR – 0.9893), with no statistical difference between the groups.
Conclusions We did not find differences between patients who treated with diet + insulin therapy and with diet + metformin. Percent of preeclampsia, preterm delivery, macrosomia and perinatal death was similar in both groups, only maternal weight gain was lower in the metformin group.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of National Center for Diabetes Research gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
